Submitted: 19 February 2015 Reference: RA/2016/02/031cp Amendment type: Response to DHCP letter and compliant response to CCC dated 02 December 2014

Size: px
Start display at page:

Download "Submitted: 19 February 2015 Reference: RA/2016/02/031cp Amendment type: Response to DHCP letter and compliant response to CCC dated 02 December 2014"

Transcription

1 PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME AND DOSAGE FORM MOTILIUM 1 mg/ml suspension COMPOSITION Each ml contains 1 mg domperidone, with 0,18 % m/v methylparaben and 0,02 % m/v propylparaben as preservatives. List of excipients: Sodium saccharin, microcrystalline cellulose and sodium carboxy-methylcellulose, sorbitol liquid non-crystallising, methylparahydroxybenzoate, propylparahydroxy-benzoate, sodium hydroxide, polysorbate, purified water. PHARMACOLOGICAL CLASSIFICATION A Anti-emetics and anti-vertigo preparations CCDS Oct 2013 & CCDS June 2014 Page 1 of 37

2 PHARMACOLOGICAL ACTION Pharmacodynamic properties Domperidone is a dopamine-receptor blocking agent. Its action on the dopaminereceptors in the chemo-emetic trigger zone produces an anti-emetic effect. Domperidone does not cross the blood-brain barrier to any appreciable degree and so exerts relatively little effect on cerebral dopaminergic receptors. Domperidone has been shown to increase antroduodenal motility and gastric emptying. There is no effect on gastric secretion. Effect on QT/QTc interval and cardiac electrophysiology In accordance with ICH-E14 guidelines, a thorough QT study was performed in healthy subjects. This study included a placebo, active comparator and positive control and was conducted using recommended and supra-therapeutic doses (10 and 20 mg administered 4 times a day). This study found a maximal difference of QTc between domperidone and placebo in LS-means in the change from baseline of 3,4 msec for 20 mg domperidone administered 4 times a day on Day 4, and the 2-sided 90 % CI (1,0 5,9 msec) did not exceed 10 msec. The QT prolongation observed in this study when domperidone was administered according to the recommended dosing regimen is not clinically relevant. This lack of clinical relevance is corroborated by pharmacokinetics and QTc interval data from two older studies which involved a 5-day treatment of 20 mg and 40 mg domperidone administered 4 times a day. ECGs were recorded prior to the study, on Day 5 at 1 hour (approximately at t max ) after the morning dose, and 3 days later. In both studies, no CCDS Oct 2013 & CCDS June 2014 Page 2 of 37

3 difference between QTc after active treatment and placebo was observed. It was therefore concluded that domperidone administration of 80 and 160 mg daily doses had no clinically significant effect on QTc in healthy subjects. Pharmacokinetic properties Absorption In fasting subjects, domperidone is rapidly absorbed after oral administration, with peak plasma concentrations occurring at approximately 60 minutes after dosing. The key pharmacokinetic parameters after a single or multiple doses (administered 4 times a day) of 10 mg domperidone base tablets to healthy subjects are presented in the table below. The C max and AUC values of domperidone increased proportionally with dose in the 10 mg to 20 mg dose range. Key domperidone pharmacokinetic parameters after a single or multiple doses (administered 4 times a day) of 10 mg domperidone base tablets to healthy subjects PK parameter Mean Domperidone 10 mg administered four times a day Day 1 Day 4 n C min, ng/ml NA 5,26 (CV: 31,1 %) C max, ng/ml 11,6 (CV: 50,8 %) 17,3 (CV: 35,4 %) t max, h a 1,02 (range: 0,52 5,02) 1,02 (range: 0,50 4,03) AUC 5h, ng.h/ml 20,4 (CV: 34,4 %) 47,8 (CV: 30,5 %) a median (range) CCDS Oct 2013 & CCDS June 2014 Page 3 of 37

4 The absolute bio-availability of oral domperidone is low (approximately 15 %) due to firstpass hepatic and intestinal metabolism. Distribution Domperidone is % bound to plasma proteins. The plasma half-life after a single oral dose is 7-9 hours in healthy subjects but is prolonged in patients with severe renal insufficiency. Metabolism Domperidone undergoes rapid and extensive hepatic metabolism by hydroxylation and N- dealkylation. In vitro metabolism experiments with diagnostic inhibitors revealed that CYP3A4 is a major form of cytochrome P-450 involved in the N-dealkylation of domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are involved in domperidone aromatic hydroxylation. Excretion Urinary and faecal excretion amount to 31 % and 66 % of the oral dose, respectively. The proportion of medicine excreted unchanged is small (approximately 1 % of urinary and 10 % of faecal excretion). CCDS Oct 2013 & CCDS June 2014 Page 4 of 37

5 Special Populations Hepatic impairment In subjects with moderate hepatic impairment (Pugh score 7 to 9, Child-Pugh rating B), the AUC and C max of domperidone is 2,9- and 1,5-fold higher, respectively, than in healthy subjects. The unbound fraction is increased by 25 %, and the terminal elimination half-life is prolonged from 15 to 23 hours. Subjects with mild hepatic impairment have a somewhat lower systemic exposure than healthy subjects based on C max and AUC, with no change in protein binding or terminal half-life. Subjects with severe hepatic impairment were not studied (see CONTRA-INDICATIONS). Renal impairment In patients with severe renal insufficiency (serum creatinine more than 6 mg/100 ml, i.e. more than 0,6 mmol/l) the elimination half-life of domperidone was increased from 7,4 to 20,8 hours, but plasma medicine levels are lower than in subjects with normal renal function. Very little unchanged medicine (approximately 1 %) is excreted via the kidneys. (see DOSAGE AND DIRECTIONS FOR USE). Paediatric patients Based on limited pharmacokinetic data, domperidone plasma concentrations in preterm neonates were consistent with those reported in adults. INDICATIONS MOTILIUM 1 mg/ml suspension is indicated for: CCDS Oct 2013 & CCDS June 2014 Page 5 of 37

6 Short-term management of delayed gastric emptying of functional origin with gastrooesophageal reflux and/or dyspepsia. Control of nausea and vomiting of central or local origin. As an anti-emetic in patients receiving cytostatic and radiation therapy. Facilitation of radiological examination of the upper gastro-intestinal tract. CONTRA-INDICATIONS MOTILIUM is contra-indicated in the following situations: Known hypersensitivity to domperidone or any of its excipients. Prolactin-releasing pituitary tumour (prolactinoma). Co-administration with other potent CYP3A4 inhibitors which have been shown to cause QT interval prolongation such as fluconazole, itraconazole, ketoconazole, voriconazole, posaconazole, clarithromycin, erythromycin, azithromycin, roxithromycin, amiodarone, telithromycin, amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir and quinolones (see WARNINGS AND SPECIAL PRECAUTIONS and INTERACTIONS). Co-administration with medicines known to induce Torsades de Pointes and/or prolong the QT interval e.g. cisapride, class 1A antidysrythmics. Hypokalaemia, hypomagnesaemia. Bradycardia or heart block. Pre-existing cardiac disease. Known congenital long QT interval or family history thereof. CCDS Oct 2013 & CCDS June 2014 Page 6 of 37

7 Whenever stimulation of gastric motility might be dangerous, e.g. in the presence of gastro-intestinal haemorrhage, mechanical obstruction or perforation. In patients with moderate or severe hepatic impairment (see Pharmacokinetic properties). WARNINGS AND SPECIAL PRECAUTIONS Cardiac effects Epidemiological studies have shown that MOTILIUM is associated with an increased risk of serious ventricular dysrhythmias or sudden cardiac death (see SIDE-EFFECTS). These studies suggested that this increased risk may be higher in patients older than 60 years of age or in patients taking oral doses greater than 30 mg per day. Therefore, MOTILIUM should be used with caution in older patients. Medicine interaction potential The main metabolic pathway of domperidone is through CYP3A4. In vitro and human data show that the concomitant use of medicines that significantly inhibit this enzyme may result in increased plasma levels of domperidone. Co-administration of MOTILIUM with potent CYP3A4 inhibitors which have been shown to cause QT interval prolongation is contraindicated (see CONTRA-INDICATIONS). Caution should be exercised when MOTILIUM is co-administered with potent CYP3A4 inhibitors which have not been shown to cause QT interval prolongation, and patients should be monitored closely for signs and symptoms of adverse reactions (see SIDE- EFFECTS). CCDS Oct 2013 & CCDS June 2014 Page 7 of 37

8 Caution should be exercised when MOTILIUM is co-administered with medicines which have been shown to cause QT interval prolongation and patients should be monitored closely for signs or symptoms of cardiovascular adverse reactions (see SIDE-EFFECTS). Examples include: Anti-arrhythmias class IA (e.g. disopyramide, quinidine). Anti-arrhythmias class III (e.g. amiodarone, dofetilide, dronedarone, ibutilide, sotalol). Certain antipsychotics (e.g. haloperidol, pimozide, sertindole). Certain antidepressants (e.g. citalopram, escitalopram). Certain antibiotics (e.g. levofloxacin, moxifloxacin and quinolones). Certain antifungal medicines (e.g. pentamidine). Certain antimalarial medicines (e.g. halofantrine). Certain gastro-intestinal medicines (e.g. dolasetron). Certain medicines in cancer (e.g. toremifene, vandetanib). Certain other medicines (e.g. bepridil, methadone). The above list is representative and not exhaustive. Domperidone base Antacids and anti-secretory medicines should not be taken simultaneously with oral formulations of MOTILIUM as they lower the oral bioavailability of MOTILIUM. When used concomitantly, MOTILIUM should be taken before meals and antacids or anti-secretory medicines after meals. Excipients CCDS Oct 2013 & CCDS June 2014 Page 8 of 37

9 MOTILIUM oral suspension contains sorbitol and may be unsuitable for patients with sorbitol intolerance. Effects on ability to drive and use machines Dizziness and somnolence have been observed following use of MOTILIUM (see SIDE-EFFECTS). Therefore, patients should be advised not to drive or use machinery or engage in other activities requiring mental alertness and coordination until they have established how MOTILIUM affects them. INTERACTIONS The main metabolic pathway of domperidone is through CYP3A4. In vitro and human data show that the concomitant use of medicines that significantly inhibit this enzyme may result in increased plasma levels of domperidone. When MOTILIUM was co-administered with potent CYP3A4 inhibitors which have been shown to cause QT interval prolongation, clinically relevant changes in QT intervals were observed. Therefore, co-administration of MOTILIUM with certain medicines is contraindicated (see CONTRA-INDICATIONS). Caution should be exercised when MOTILIUM is co-administered with potent CYP3A4 inhibitors which have not been shown to cause QT interval prolongation or medicines which have been shown to cause QT interval prolongation (see WARNINGS AND SPECIAL PRECAUTIONS). CCDS Oct 2013 & CCDS June 2014 Page 9 of 37

10 Concomitant administration of anti-cholinergic medicines (e.g. dextromethorphan, diphenhydramine) may antagonise the anti-dyspeptic effects of MOTILIUM. Since MOTILIUM has gastro-kinetic effects, it could influence the absorption of concomitant orally administered medicines, particularly those with sustained release or enteric coated formulations. However, in patients already stabilised on digoxin or paracetamol, concomitant administration of MOTILIUM did not influence the blood levels of these medicines. MOTILIUM may also be given with: Neuroleptics, the action of which it does not potentiate Dopaminergic agonists (bromocriptine, L-dopa), whose unwanted peripheral effects such as digestive disorders, nausea and vomiting it suppresses without counteracting their central properties. Reduced gastric acidity impairs the absorption of MOTILIUM. Oral bioavailability is decreased by prior concomitant administration of cimetidine and sodium bicarbonate. As MOTILIUM interferes with serum prolactin levels, it may interfere with other hypoprolactinaemic agents and with some diagnostic tests. PREGNANCY AND LACTATION The safety of use during pregnancy and lactation has not been established. CCDS Oct 2013 & CCDS June 2014 Page 10 of 37

11 Domperidone is excreted in human breast milk therefore breast feeding is not recommended for mothers who are taking MOTILIUM suspension. DOSAGE AND DIRECTIONS FOR USE It is recommended to take oral MOTILUM minutes before meals. If taken after meals, absorption of the medicine is somewhat delayed. Adults and adolescents 12 years of age and weighing 35 kg, and children weighing 35 kg The dose of MOTILIUM suspension should be the lowest effective dose for the individual situation (typically 30 mg/day) with a maximum daily oral dose of 40 mg. Usually, the maximum treatment duration should not exceed one week for the treatment of acute nausea and vomiting. If nausea and vomiting persists for longer than one week, patients should consult their medical practitioners. For other indications, the initial duration of treatment is up to four weeks. If treatment exceeds four weeks, patients should be re-evaluated and the need for continued treatment reassessed. Formulation (domperidone per unit) Oral suspension (1 mg/ml) Dosage 10 ml three to four times per day Maximum dose per day 40 mg (40 ml of 1 mg/ml oral suspension) Infants and children < 12 years of age and weighing < 35 kg, and adults and adolescents weighing < 35 kg. CCDS Oct 2013 & CCDS June 2014 Page 11 of 37

12 The dose of MOTILIUM suspension should be the lowest effective dose. The total daily dose is dependent on body weight (see table below). Since metabolic functions and the blood-brain barrier are not fully developed in the first months of life, the risk of neurological side effects is higher in young children (see SIDE-EFFECTS). Overdosing may cause nervous system disorders in children (see KNOWN SYMPTOMS OF OVERDOSE AND PARTICULARS OF ITS TREATMENT). The dose should be determined accurately based on body weight and not exceed the recommended maximum individual and daily dose in neonates, infants, toddlers and children. Usually, the maximum treatment duration should not exceed one week for the treatment of acute nausea and vomiting. For other indications, the initial duration of treatment is up to four weeks. If treatment exceeds four weeks, patients should be re-evaluated and the need for continued treatment reassessed. Film-coated tablets are unsuitable for use in children, adults and adolescents weighing less than 35 kg. Formulation (domperidone per unit) Oral suspension (1 mg/ml) Dosage 0,25 mg/kg three to four times per day Maximum dose per day 35 mg (1 mg/kg but no more than 35 ml) Renal impairment Since the elimination half-life of domperidone is prolonged in severe renal impairment (serum creatinine > 6 mg/100 ml, i.e. > 0,6 mmol/l), the dosing frequency of MOTILIUM should be reduced to once or twice daily, depending on the severity of the impairment, and the dose may need to be reduced. Patients with severe renal impairment should be reviewed regularly. CCDS Oct 2013 & CCDS June 2014 Page 12 of 37

13 Hepatic impairment MOTILIUM is contraindicated for patients with moderate (Child-Pugh 7 to 9) or severe (Child-Pugh > 9) hepatic impairment (see CONTRA-INDICATIONS). Dose adjustment is not required for patients with mild (Child-Pugh 5 to 6) hepatic impairment (see Pharmacokinetic properties). Directions for use Mix the contents of the bottle completely using a gentle tilting motion to avoid the formation of foam. Directions for opening the bottle: The bottle comes with a child-proof cap, and should be opened as follows: - Push the plastic screw cap down while turning it counter clockwise. - Remove the unscrewed cap. SIDE EFFECTS Clinical Trial Data The adverse reactions are ranked by frequency, using the following convention: Very common ( 1/10); common ( 1/100, < 1/10); uncommon ( 1/1 000, < 1/100); rare ( 1/10 000, < 1/1 000); very rare (< 1/10 000), including isolated reports. Psychiatric disorders Common: Depression, anxiety, libido decreased/loss of libido. CCDS Oct 2013 & CCDS June 2014 Page 13 of 37

14 Nervous system disorders Common: Headache, somnolence, akathisia. Gastro-intestinal disorders Common: Diarrhoea. Immune system disorders Uncommon: Hypersensitivity. Skin and subcutaneous tissue disorders Common: Rash, pruritus. Uncommon: Urticaria. Reproductive system and breast disorders Common: Breast enlargement/ gynaecomastia, breast tenderness, galactorrhoea, amenorrhoea, breast pain, menstruation irregular, lactation disorder. Uncommon: Breast discharge, breast swelling. CCDS Oct 2013 & CCDS June 2014 Page 14 of 37

15 General disorders and administration site conditions Common: Asthenia. Dry mouth has also been reported. Post-marketing In addition to the adverse effects reported during clinical studies and listed above, the following adverse drug reactions have been reported post-marketing: Immune System Disorders Anaphylactic reaction (including anaphylactic shock). Psychiatric Disorders Agitation, nervousness. Nervous System Disorders Dizziness, extrapyramidal disorder, convulsion. Cardiac Disorders Sudden cardiac death, serious ventricular dysrhythmias (see WARNINGS AND SPECIAL PRECAUTIONS). Skin and Subcutaneous Tissue Disorders CCDS Oct 2013 & CCDS June 2014 Page 15 of 37

16 Angioedema. Renal and Urinary Disorders Urinary retention. Investigations Liver function test abnormal, blood prolactin increased. Paediatric population Extrapyramidal disorder occurs in neonates and infants. Central nervous system-related effects of convulsion, agitation and somnolence have also been reported in infants and children. KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT Symptoms and signs Overdose has been reported primarily in infants and children. Symptoms of overdosage may include agitation, altered consciousness, convulsion, disorientation, somnolence and extrapyramidal reactions. Treatment There is no specific antidote to domperidone, but in the event of overdosage, gastric lavage as well as the administration of activated charcoal may be useful. Symptomatic and supportive measures are recommended. Anticholinergic or anti-parkinson medicines may be helpful in controlling the extrapyramidal reactions. CCDS Oct 2013 & CCDS June 2014 Page 16 of 37

17 IDENTIFICATION White suspension with a sweet taste. PRESENTATION 100 ml amber glass bottles. STORAGE INSTRUCTIONS Store at or below 25 o C. Protect from light. KEEP OUT OF REACH OF CHILDREN. REGISTRATION NUMBER V/5.7.2/19 NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION JANSSEN PHARMACEUTICA (PTY) LTD. (Reg No.: 1980/011122/07) Building 6, Country Club Estate, CCDS Oct 2013 & CCDS June 2014 Page 17 of 37

18 21 Woodlands Drive, Woodmead, 2191 Tel: +27 (11) Nam. Reg. No.: 04/5.7.1/0277 NS 2 Botswana Reg. No.: B S3 Zimbabwe Reg. No.: 90/16.4/2379 PIM DATE OF PUBLICATION OF THIS PACKAGE INSERT 02 April 2015 CCDS Oct 2013 & CCDS June 2014 Page 18 of 37

19 VOUBILJET SKEDULERINGSTATUS Skedule 4 EIENDOMSNAAM EN DOSEERVORM MOTILIUM 1 mg/ml suspensie SAMESTELLING Elke ml bevat 1 mg domperidoon, met 0,18 % m/v metielparabeen en 0,02 % m/v propielparabeen as preserveermiddels. Lys van mengmiddels: Natriumsakkarien, mikrokristallyne sellulose en natriumkarboksimetielsellulose, sorbitol nie-kristalliserende vloeistof, metielparahidroksiebensoaat, propielparahidroksiebensoaat, natriumhidroksied, polisorbaat, gesuiwerde water. FARMAKOLOGIESE KLASSIFIKASIE A Anti-emetika en antivertigopreparate FARMAKOLOGIESE WERKING CCDS Oct 2013 & CCDS June 2014 Page 19 of 37

20 Farmakodinamiese eienskappe Domperidoon is 'n dopamienreseptor blokkeerder. Die werking daarvan op die dopamienreseptore in die chemo-emetiese snellerarea veroorsaak 'n anti-emetiese effek. Daar vind geen noemenswaardige kruising van domperidoon deur die bloedbreinskans plaas nie en derhalwe oefen dit weinig effek op die dopaminergiese reseptore van die serebrum uit. Daar is aangetoon dat domperidoon die motiliteit van die dunderm en maaglediging verhoog. Daar is geen effek op maagafskeiding nie. Effek op QT/QTc-interval en kardiale elektrofisiologie In ooreenstemming met ICH-E14 riglyne, is 'n deeglike QT-studie uitgevoer in gesonde persone. Hierdie studie het 'n plasebo, 'n aktiewe vergelyker en 'n positiewe kontrole ingesluit en daar is gebruik gemaak van die aanbevole en supra-terapeutiese dosisse (10 en 20 mg, 4 keer per dag toegedien). Hierdie studie het aangetoon dat daar 'n maksimale verskil van QTc is tussen domperidoon en plasebo in kleinste kwadraat-gemiddelde in die verandering vanaf basislyn van 3,4 msek vir 20 mg domperidoon, 4 keer per dag toegedien, op Dag 4. Die 2-kantige 90 % VI (1,0-5,9 msek) het nie 10 msek oorskry nie. Die QT-verlenging wat in hierdie studie waargeneem is toe domperidoon volgens die aanbevole doseringsregimen toegedien is, is nie klinies relevant nie. Hierdie gebrek aan kliniese relevansie word gestaaf deur die farmakokinetiese en QTcinterval data uit twee ouer studies wat 'n 5-dag behandeling van 20 mg en 40 mg domperidoon, 4 keer per dag toegedien, behels het. EKGs is voor die studie, op Dag 5 by CCDS Oct 2013 & CCDS June 2014 Page 20 of 37

21 1 uur (ongeveer by t maks ) na die oggenddosis en 3 dae later, opgeneem. In beide studies is daar geen verskil tussen die QTc na aktiewe behandeling en plasebo waargeneem nie. Die gevolgtrekking was dus dat die toediening van daaglikse dosisse van 80 en 160 mg domperidoon geen klinies beduidende uitwerking op QTc by gesonde persone het nie. Farmakokinetiese eienskappe Absorpsie By vastende persone word domperidoon vinnig na orale toediening geabsorbeer, met piekplasmakonsentrasies teen ongeveer 60 minute na dosering. Die hooffarmakokinetiese parameters na 'n enkele dosis of veelvuldige dosisse (4 keer per dag toegedien) van 10 mg domperidoonbasis tablette aan gesonde persone word in die tabel hieronder weergegee. Die K maks en AOK waardes van domperidoon het proporsioneel met die dosis in die 10 mg tot 20 mg dosisreeks toegeneem. Hoof-farmakokinetiese parameters na 'n enkele dosis of veelvuldige dosisse (4 keer per dag toegedien) van 10 mg domperidoonbasis tablette aan gesonde persone PK-parameter Gemiddelde Domperidoon 10 mg, vier keer per dag toegedien Dag 1 Dag 4 n K min, ng/ml nvt 5,26 (VK: 31,1 %) K max, ng/ml 11,6 (VK: 50,8 %) 17,3 (VK: 35,4 %) t maks, h a 1,02 (reeks: 0,52 5,02) 1,02 (reeks: 0,50 4,03) AOK 5h, ng.h/ml 20,4 (VK: 34,4 %) 47,8 (VK: 30,5 %) a mediaan (reeks) CCDS Oct 2013 & CCDS June 2014 Page 21 of 37

22 Die absolute biobeskikbaarheid van orale domperidoon is laag (ongeveer 15 %) weens die eerstedeurgang hepatiese en intestinale metabolisme. Verspreiding Domperidoon word % aan plasmaproteïene gebind. Die plasmahalfleeftyd na 'n enkele mondelike dosis is 7-9 uur in gesonde indiwidue maar is effens langer by pasiënte met erge nierversaking. Metabolisme Domperidoon ondergaan snelle en uitgebreide hepatiese metabolisme deur hidroksilasie en N-dealkilering. In vitro metabolisme eksperimente met diagnostiese inhibeerders het bekend gemaak dat CYP3A4 n belangrike vorm van sitochroom P-450 is en betrokke is in die N-dealkilering van domperidoon, terwyl CYP3A4, CYP1A2 en CYP2E1 betrokke is by die aromatiese hidroksilasie van domperidoon. Uitskeiding Daar word onderskeidelik 31 % en 66 % van die mondelike dosis urinêr en fekaal uitgeskei. Die gedeelte van die medisyne wat onveranderd uitgeskei word is klein (ongeveer 1 % van die urinêre en 10 % van die fekale uitskeiding). CCDS Oct 2013 & CCDS June 2014 Page 22 of 37

23 Spesiale populasies Swak lewerfunksie By persone met matige lewerontoereikendheid (Pugh-telling 7-9, Child-Pugh gradering B), is die AOK en K maks van domperidoon onderskeidelik 2,9- en 1,5 keer hoër as by gesonde persone. Die vrye gedeelte neem 25 % toe en die terminale eliminasiehalfleeftyd is verleng vanaf 15 tot 23 uur. Persone met ligte lewerontoereikendheid toon ietwat laer sistemiese blootstelling as gesonde persone, op grond van die K maks en die AOK, sonder verandering in proteïenbinding of terminale halfleeftyd. Persone met ernstige lewerontoereikendheid is nie bestudeer nie (sien KONTRA-INDIKASIES). Swak nierfunksie By pasiënte met ernstige swak nierfunksie (serumkreatinien> 6 mg/100 ml, dus > 0,6 mmol/l) is die halfleeftyd van domperidoon van 7,4 tot 20,8 uur verleng, maar die plasmageneesmiddelkonsentrasie is laer as by pasiënte met 'n normale nierfunksie. Baie min geneesmiddel (ongeveer 1 %) word in onveranderde vorm deur die niere uitgeskei (sien DOSIS EN GEBRUIKSAANWYSINGS). Pediatriese pasiënte Gebaseer op beperkte farmakokinetiese data is die plasmakonsentrasies van domperidoon in vroeggebore neonate in ooreenstemming met dié wat by volwassenes aangemeld is. CCDS Oct 2013 & CCDS June 2014 Page 23 of 37

24 INDIKASIES MOTILIUM 1 mg/ml suspensie word aangedui vir: Korttermyn behandeling van vertraagde maaglediging van funksionele oorsprong met gastro-esofageale refluks en/of dispepsie. Beheer van naarheid en braking van sentrale of plaaslike oorsprong. As 'n anti-emetiese middel by pasiënte wat sitostatika gebruik en stralingsterapie ontvang. Om radiologiese ondersoeke van die boonste gastro-intestinale kanaal te vergemaklik. KONTRA-INDIKASIES MOTILIUM word teenaangedui by die volgende toestande: Bekende hipersensitiwiteit vir domperidoon of enige van die bestanddele daarvan. Prolaktienvrystellende hipofisêre tumor (prolaktinoom). Gesamentlike toediening met ander kragtige CYP3A4- remmers waarvan aangetoon is dat hulle QT-interval verlenging veroorsaak soos flukonasool, itrakonasool, ketokonasool, vorikonasool, posakonasool, klaritromisien, eritromisien, asitromisien, roksitromisien, amiodaroon, telitromisien, amprenavir, atasanavir, fosamprenavir, indinavir, nelfinavir, ritonavir, sakinavir en kinolone (sien WAARSKUWINGS EN SPESIALE VOORSORGMAATREËLS en INTERAKSIES). Gesamentlike toediening met medisyne bekend vir induksie van Torsades de Pointes en/of wat die QT interval verleng, bv.sisapried, klas 1A-anti-disritmiese middels. Hipokalemie, hipomagnesemie. CCDS Oct 2013 & CCDS June 2014 Page 24 of 37

25 Bradikardie of hartblok. Reeds bestaande hartsiekte. Bekende kongenitale lang-qt interval of familiegeskiedenis daarvan. Wanneer stimulering van maagbeweeglikheid gevaarlik kan wees, bv. in die teenwoordigheid van gastro-intestinale bloeding, meganiese obstruksie of perforasie. By pasiënte met matige tot ernstige lewerinkorting (sien Farmakokinetiese eienskappe). WAARSKUWINGS EN SPESIALE VOORSORGMAATREËLS Uitwerking op die hart Epidemiologiese studies het getoon dat MOTILIUM in verband gebring kan word met 'n hoër risiko op ernstige ventrikelaritmie of skielike hartdood (sien NEWE-EFFEKTE). Hierdie studies het daarop gedui dat die risiko hoër kan wees by pasiënte ouer as 60 jaar of by pasiënte wat dosisse neem van meer as 30 mg per dag. Daarom moet MOTILIUM met omsigtigheid gebruik word by ouer pasiënte. Moontlike interaksies met medisyne Domperidoon word hoofsaaklik deur CYP3A4 gemetaboliseer. In vitro en menslike data wys daarop dat gelyktydige gebruik van medisynes wat hierdie ensiem sterk rem, die plasmakonsentrasie van domperidoon kan laat styg. Gesamentlike toediening van MOTILIUM met kragtige CYP3A4- remmers waarvan aangetoon is dat dit QT-interval verlenging veroorsaak, is teenaangedui (sien KONTRA-INDIKASIES). CCDS Oct 2013 & CCDS June 2014 Page 25 of 37

26 Versigtigheid moet uitgeoefen word wanneer MOTILIUM toegedien word saam met kragtige CYP3A4-remmers waarvan daar nie QT-interval verlenging aangetoon is nie en pasiënte moet noukeurig gemoniteer word vir tekens en simptome van ongunstige reaksies (sien NEWE-EFFEKTE). Versigtigheid moet uitgeoefen word wanneer MOTILIUM toegedien word saam met medisynes waarvan daar QT-interval verlenging aangetoon is en pasiënte moet noukeurig gemoniteer word vir tekens en simptome van ongunstige reaksies (sien NEWE- EFFEKTE). Voorbeelde sluit in: Antidisritmiese middels klas IA (bv. disopiramied, kinidien) Antidisritmiese middels klas III (bv. amiodaroon, dofetilied, dronedaroon, ibutilied, sotalol). Sekere antipsigotika (bv. haloperidol, pimosied, sertindool). Sekere antidepressante (bv. sitalopraam, essitalopraam). Sekere antibiotika (bv. levofloksasien, moksifloksasien en kinolone). Sekere swamweermiddels (bv. pentamidien). Sekere antimalariamiddels (bv. halofantrien). Sekere gastro-intestinale medisyne (bv. dolasetron). Sekere medisynes vir kanker (bv. toremifeen, vandetanib). Sekere ander medisynes (bv. bepridil, metadoon). Die bogenoemde lys is verteenwoordigend en nie volledig nie. Domperidoonbasis Teensuurmiddels en anti-sekretoriese medisyne moet nie saam met mondelike formulerings van MOTILIUM geneem word nie aangesien hulle die orale CCDS Oct 2013 & CCDS June 2014 Page 26 of 37

27 biobeskikbaarheid van MOTILIUM verminder. Wanneer albei gebruik word, moet MOTILIUM voor etes geneem word en teensuurmiddels of anti-sekretoriese medisyne na etes. Mengmiddels MOTILIUM orale suspensie bevat sorbitol en kan moontlik nie geskik wees vir pasiënte met sorbitol intoleransie nie. Effek op die vermoë om te bestuur en masjinerie te gebruik Duiseligheid en slaperigheid is waargeneem na gebruik van MOTILIUM (sien NEWE-EFFEKTE). Pasiënte moet gevolglik aangeraai word om nie te bestuur of masjinerie te gebruik, of betrokke te raak by ander aktiwiteite wat verstandelike wakkerheid en koördinasie verg nie, totdat hulle weet hoe MOTILIUM hulle beïnvloed. INTERAKSIES Domperidoon word hoofsaaklik deur CYP3A4 gemetaboliseer. In vitro en menslike data wys daarop dat gelyktydige gebruik van medisynes wat hierdie ensiem sterk rem, die plasmakonsentrasie van domperidoon kan laat styg. Toe MOTILIUM toegedien is saam met kragtige CYP3A4-remmers waarvan aangetoon is dat hulle die QT-interval verleng, is klinies relevante veranderinge in QT-intervalle waargeneem. Gevolglik is gesamentlike toediening van MOTILIUM met sekere medisyne teenaangedui (sien KONTRA-INDIKASIES). CCDS Oct 2013 & CCDS June 2014 Page 27 of 37

28 Versigtig moet uitgeoefen word wanneer MOTILIUM toegedien word saam met kragtige CYP3A4-remmers waarvan nie aangetoon is dat hulle die QT-interval verleng nie, of medisyne waarvan reeds aangetoon is dat hulle die QT-interval verleng (sien WAARSKUWINGS EN SPESIALE VOORSORGMAATREËLS). Gelyktydige toediening van anticholinergiese medisynes (bv. dekstrometorfaan, difenhidramien) kan die anti-dispeptiese effekte van MOTILIUM antagoniseer. Aangesien MOTILIUM n gastrokinetiese uitwerking het, kan dit die absorpsie van ander medisyne wat gelyktydig mondelik toegedien word beïnvloed, veral die wat stadig vrygestel word of enteriesbedekte formulerings. By pasiënte wat reeds op digoksien of parasetamol gestabiliseer is, het gepaardgaande toediening van MOTILIUM egter nie die bloedvlakke van hierdie medisynes beïnvloed nie. MOTILIUM kan ook gegee word met: Neuroleptika; die werking hiervan word nie gepotensieer nie. Dopaminergiese agoniste (broomkriptien, L-dopa), waarvan die ongewenste perifere effekte soos verteringsteurnisse, naarheid en braking onderdruk word sonder om hul sentrale eienskappe teen te werk. Verminderde maagsuur belemmer die absorpsie van MOTILIUM. Mondelike biobeskikbaarheid word verminder deur voorafgaande toediening van simetidien en natriumbikarbonaat. CCDS Oct 2013 & CCDS June 2014 Page 28 of 37

29 Omdat MOTILIUM die serumprolaktienvlakke beïnvloed, kan dit moontlik inmeng met ander hipoprolaktinemiese medisynes en sommige diagnostiese toetse. SWANGERSKAP EN LAKTASIE Die veiligheid van gebruik tydens swangerskap en borsvoeding is nie bepaal nie. Domperidoon word in menslike borsmelk uitgeskei, daarom word borsvoeding nie aanbeveel vir moeders wat MOTILIUM suspensie neem nie. DOSIS EN GEBRUIKSAANWYSINGS Dit word aanbeveel dat mondelike MOTILIUM minute voor maaltye geneem word. Indien dit na maaltye geneem word, is die absorpsie van die medisyne ietwat vertraag. Volwassenes en adolessente 12 jaar oud, wat 35 kg weeg en kinders wat 35 kg weeg Die dosis van MOTILIUM suspensie moet die laagste doeltreffende dosis vir die individuele situasie wees (tipies 30 mg/dag), met 'n maksimum daaglikse orale dosis van 40 mg. Gewoonlik moet die maksimum duur van behandeling nie meer as een week wees vir die behandeling van akute naarheid en braking nie. As naarheid en braking vir langer as 'n week aanhou, moet pasiënte hul mediese praktisyns raadpleeg. Vir ander indikasies is die aanvanklike duur van behandeling tot vier weke. Indien die behandeling vier CCDS Oct 2013 & CCDS June 2014 Page 29 of 37

30 weke oorskry, moet pasiënte herevalueer word en die behoefte vir voortgesette behandeling heroorweeg word. Formulering (domperidoon per eenheid) Orale suspensie (1 mg/ml) Dosis 10 ml drie tot vier keer per dag Maksimum dosis per dag 40 mg (40 ml van 'n 1 mg/ml orale suspensie) Babas en kinders < 12 jaar oud en wat < 35 kg weeg en volwassenes en adolessente wat < 35 kg weeg Die dosis van die MOTILIUM suspensie moet die laagste doeltreffende dosis wees. Die totale daaglikse dosis is afhanklik van die liggaamsgewig (sien tabel hieronder). Aangesien die metaboliese funksies en die bloedbreinskans nie volledig ontwikkel is binne die eerste lewensmaande nie, is die risiko van neurologiese newe-effekte hoër by jong kinders (sien NEWE-EFFEKTE). Oordosering kan senuweestelsel versteurings by kinders veroorsaak (sien BEKENDE SIMPTOME VAN OORDOSERING EN BESONDERHEDE VAN DIE BEHANDELING DAARVAN). Die dosis moet akkuraat volgens die liggaamsgewig bepaal word en moet nie die aanbevole maksimum individuele en daaglikse dosis by pasgeborenes, babas, kleuters en kinders oorskry nie. Gewoonlik moet die maksimum duur van behandeling nie meer as een week wees vir die behandeling van akute naarheid en braking nie. Vir ander indikasies is die aanvanklike duur van behandeling tot vier weke. Indien die behandeling vier weke oorskry, moet pasiënte herevalueer word en die behoefte vir voortgesette behandeling heroorweeg word. Die filmbedekte tablette is nie geskik vir gebruik by kinders, volwassenes en adolessente wat minder as 35 kg weeg nie. CCDS Oct 2013 & CCDS June 2014 Page 30 of 37

31 Formulering (domperidoon per eenheid) Orale suspensie (1 mg/ml) Dosis 0,25 mg/kg drie tot vier keer per dag Maksimum dosis per dag 35 mg (1 mg/kg maar nie meer as 35 ml nie) Swak nierfunksie Aangesien die eliminasie-halfleeftyd van domperidoon langer duur by ernstige verswakte nierfunksie (serumkreatinien > 6 mg/100 ml, d.i. > 0,6 mmol/l), moet die frekwensie van dosering van MOTILIUM verminder word na een- tot tweemaal per dag, afhangende van hoe ernstig die inkorting is, en die dosis sal moontlik verlaag moet word. Pasiënte met ernstig verswakte nierfunksie moet gereeld nagegaan word. Swak lewerfunksie MOTILIUM is teenaangedui vir pasiënte met matige (Child-Pugh 7 tot 9) of ernstige (Child- Pugh > 9) aangetaste lewerfunksie (sien KONTRA-INDIKASIES). Dosisaanpassing is nie nodig vir pasiënte met lig aangetaste (Child-Pugh 5 tot 6) lewerfunksie nie (sien Farmakokinetiese eienskappe). Gebruiksaanwysings Meng die inhoud van die bottel deeglik deur dit sagkens te kantel om die voorkoms van skuim te vermy. Aanwysings om die bottel oop te maak: Die bottel word voorsien met ʼn kind-bestande doppie, en moet soos volg oopgemaak word: CCDS Oct 2013 & CCDS June 2014 Page 31 of 37

32 - Druk die plastiese skroefdoppie ondertoe af terwyl dit antikloksgewys gedraai word. - Verwyder die losgedraaide doppie. NEWE-EFFEKTE Kliniese proewe data Die ongunstige geneesmiddelreaksies is volgens voorkomsfrekwensie ingedeel, in ooreenstemming met die volgende gebruik: Baie algemeen ( 1/10); algemeen ( 1/100, < 1/10); ongewoon ( 1/1 000, < 1/100); seldsaam ( 1/10 000, < 1/1 000); baie seldsaam (< 1/10 000), insluitende enkele berigte. Psigiatriese siektes Algemeen: Depressie, angs, afname/verlies van libido. Senuweestelselsiektes Algemeen: Hoofpyn, lomerigheid, akatisie. Gastro-intestinale siektes Algemeen: Diarree. Immuunstelselsiekte Ongewoon: CCDS Oct 2013 & CCDS June 2014 Page 32 of 37

33 Hipersensitiwiteit Vel- en onderhuidse weefselsiektes Algemeen: Uitslag, pruritus. Ongewoon: Urtikaria. Voortplantingstelsel- en borssiektes Algemeen: Borsvergroting/ginekomastie, borsteerheid, galaktorree, amenoree, borspyn, ongereelde menstruasie, laktasie afwyking. Ongewoon: Borsafskeiding, borste geswel. Algemene siektes en toestande by die plek van toediening Algemeen: Astenie. Droë mond is ook aangemeld. Nabemarking Bykomend tot die ongunstige newe-effekte wat gedurende kliniese proewe aangemeld is en hierbo gelys word, is die volgende newe-effekte na bemarking aangemeld: CCDS Oct 2013 & CCDS June 2014 Page 33 of 37

34 Immuunstelselsiekte Anafilaktiese reaksie (insluitende anafilaktiese skok). Psigiatriese siektes Agitasie, senuweeagtigheid. Senuweestelselsiektes Duiseligheid, ekstrapiramidale newe-effekte, konvulsies. Hartsiektes Skielike hartstilstand, ernstige ventrikulêre disritmieë (sien WAARSKUWINGS EN SPESIALE VOORSORGMAATREËLS). Vel- en onderhuidse weefselsiektes Angio-edeem Nier- en urienwegsiektes Urienretensie Ondersoeke Lewerfunksietoets abnormaal, toename in bloedprolaktienvlakke. Pediatriese bevolking CCDS Oct 2013 & CCDS June 2014 Page 34 of 37

35 Ekstrapiramidale versteurings kom hoofsaaklik voor by neonate en babas. Ander sentrale senuweestelsel-verwante effekte soos konvulsies, onrustigheid en lomerigheid is ook by babas en kinders aangemeld. BEKENDE SIMPTOME VAN OORDOSERING EN BESONDERHEDE VAN DIE BEHANDELING DAARVAN Tekens en simptome Oordosering is hoofsaaklik by babas en kinders aangemeld. Simptome van oordosering kan opgewondenheid, veranderde bewussyn, konvulsies, disoriëntasie, lomerigheid en ekstrapiramidale reaksies insluit. Behandeling Daar bestaan geen spesifieke teenmiddel vir domperidoon nie, maar maagspoeling asook die toediening van geaktiveerde houtskool kan in die geval van oordosering van nut wees. Simptomatiese en ondersteunende stappe word aanbeveel. Anticholinergiese of anti- Parkinson medisyne kan van nut wees by die beheer van ekstrapiramidale reaksies. IDENTIFIKASIE 'n Wit suspensie met ʼn soet smaak. AANBIEDING 100 ml bruin glasbottels. CCDS Oct 2013 & CCDS June 2014 Page 35 of 37

36 BERGINGSAANWYSINGS Bewaar by of benede 25 º C. Beskerm teen lig. HOU BUITE BEREIK VAN KINDERS. REGISTRASIENOMMER V/5.7.2/19 NAAM EN BESIGHEIDSADRES VAN DIE HOUER VAN DIE REGISTRASIESERTIFIKAAT JANSSEN PHARMACEUTICA (PTY) LTD. (Reg No.: 1980/011122/07) Building 6, Country Club Estate, 21 Woodlands Drive, Woodmead, 2191 Tel: +27 (11) Nam. Reg. No.: 04/5.7.1/0277 NS 2 CCDS Oct 2013 & CCDS June 2014 Page 36 of 37

37 Botswana Reg. No.: B S3 Zimbabwe Reg. No.: 90/16.4/2379 PIM DATUM VAN PUBLIKASIE VAN HIERDIE VOUBILJET 02 April 2015 CCDS Oct 2013 & CCDS June 2014 Page 37 of 37

MOTILIUM 10 mg tablets are white, circular, film-coated, biconvex tablets with m/10 imprinted on one side and JANSSEN on the other.

MOTILIUM 10 mg tablets are white, circular, film-coated, biconvex tablets with m/10 imprinted on one side and JANSSEN on the other. MOTILIUM DATASHEET NAME OF MEDICINE Domperidone base PRESENTATION MOTILIUM 10 mg tablets are white, circular, film-coated, biconvex tablets with m/10 imprinted on one side and JANSSEN on the other. USES

More information

Prokinex Version 2.0. Data Sheet

Prokinex Version 2.0. Data Sheet Name of Medicine Prokinex (Domperidone Tablets 10 mg) Presentation Data Sheet Prokinex Tablets 10mg are white, round, biconvex uncoated tablets with the inscription I36A on one side and plain on the other

More information

MOTILIUM. domperidone DATASHEET

MOTILIUM. domperidone DATASHEET MOTILIUM domperidone DATASHEET 1. PRODUCT NAME Motilium 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg domperidone base. Excipients with known

More information

Domperidon Betapharm 10 mg tablets. Summary of Product Characteristics. 1:(to be changed into local product name in each CMS after day 90)

Domperidon Betapharm 10 mg tablets. Summary of Product Characteristics. 1:(to be changed into local product name in each CMS after day 90) 1. NAME OF THE MEDICINAL PRODUCT Domperidone Betapharm10 mg, tablets 1 Summary of Product Characteristics 1:(to be changed into local product name in each CMS after day 90) 2. QUALITATIVE AND QUANTITATIVE

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report

More information

Lactose monohydrate, maize starch, talc and magnesium stearate. The capsule

Lactose monohydrate, maize starch, talc and magnesium stearate. The capsule SCHEDULING STATUS Schedule 2 PROPRIETARY NAME AND DOSAGE FORM IMODIUM CAPS capsules COMPOSITION. The other ingredients are: Lactose monohydrate, maize starch, talc and magnesium stearate. The capsule itself

More information

QA Amendment Sugar and layout 09/03/2007

QA Amendment Sugar and layout 09/03/2007 SCHEDULING STATUS: S0 QA Amendment PROPRIETARY NAME: (and dosage form) PANADO INFANT DROPS (Drops) COMPOSITION: Each 0,6 ml contains: Paracetamol Preservatives: Methylparaben Propylparaben 60 mg 0,085%

More information

DOMCET Tablet / Suspension (Domperidone maleate + Paracetamol)

DOMCET Tablet / Suspension (Domperidone maleate + Paracetamol) Published on: 23 Sep 2014 DOMCET Tablet / Suspension ( maleate + ) Composition Tablets Each film- coated tablet contains: Maleate equivalent to.. 10 mg.. 325 mg Suspension Each 5 ml of suspension contains:

More information

APPROVED PACKAGE INSERT FOR INGELVAC MYCOFLEX

APPROVED PACKAGE INSERT FOR INGELVAC MYCOFLEX APPROVED PACKAGE INSERT FOR INGELVAC MYCOFLEX Only for use by or under the supervision of persons registered in terms of or authorised in terms of section 23 (1) (c) of the Veterinary and Para-Veterinary

More information

APO-Domperidone Tablet

APO-Domperidone Tablet APO-Domperidone Tablet NAME OF THE MEDICINE Domperidone maleate Chemical Name: 5-Chloro-1-[1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidin-4- yl]-1,3-dihydro-2h-benzimidazol-2-one hydrogen

More information

INSTRUCTION for medical use DOMRID SR

INSTRUCTION for medical use DOMRID SR APPROVED Order of the Ministry of Health of Ukraine 15.09.2016 973 Registration certificate UA/8976/03/01 INSTRUCTION for medical use DOMRID SR Composition: active substance: domperidone maleate; 1 tablet

More information

AUSTRALIAN PRODUCT INFORMATION APO-DOMPERIDONE (DOMPERIDONE MALEATE) TABLET

AUSTRALIAN PRODUCT INFORMATION APO-DOMPERIDONE (DOMPERIDONE MALEATE) TABLET AUSTRALIAN PRODUCT INFORMATION APO-DOMPERIDONE (DOMPERIDONE MALEATE) TABLET 1 NAME OF THE MEDICINE Domperidone maleate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains domperidone maleate,

More information

INDICATIONS: For the relief of mild to moderate pain and fever such as headaches, toothache and pain associated with colds and flu.

INDICATIONS: For the relief of mild to moderate pain and fever such as headaches, toothache and pain associated with colds and flu. SCHEDULING STATUS: S0 PROPRIETARY NAME: (AND DOSAGE FORM) PANADO EFFERVESCENT (TABLETS) COMPOSITION: Each tablet contains: 500 mg paracetamol. Sugar free. PHARMACOLOGICAL CLASSIFICATION: A 2.7 Antipyretic

More information

FOR ANIMAL USE ONLY. BERENIL R.T.U. Reg. No. G2702 (Act 36/1947) Namibia Reg. No. V00/17.4.2/638 NS0

FOR ANIMAL USE ONLY. BERENIL R.T.U. Reg. No. G2702 (Act 36/1947) Namibia Reg. No. V00/17.4.2/638 NS0 FOR ANIMAL USE ONLY BERENIL R.T.U. Reg. No. G2702 (Act 36/1947) Namibia Reg. No. V00/17.4.2/638 NS0 INDICATIONS Berenil R.T.U. cures and prevents Redwater in cattle and cures biliary fever in dogs and

More information

Package Insert. Other excipients include: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium,

Package Insert. Other excipients include: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, Package Insert SCHEDULING STATUS Schedule 4 PROPIETARY NAME & DOSAGE FORM ZYTIGA 250 mg tablets COMPOSITION Each tablet contains 250 mg of abiraterone acetate. Other excipients include: lactose monohydrate,

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.

More information

PACKAGE INSERT. Each JURNISTA 4 mg extended-release tablet contains 4,36 mg and delivers 4 mg hydromorphone

PACKAGE INSERT. Each JURNISTA 4 mg extended-release tablet contains 4,36 mg and delivers 4 mg hydromorphone PACKAGE INSERT SCHEDULING STATUS Schedule 6 PROPRIETARY NAME AND DOSAGE FORM JURNISTA JURNISTA 4 mg extended-release tablets 8 mg extended-release tablets JURNISTA 16 mg extended-release tablets Contains

More information

CCDS Jan 2013 Page 1 of 40

CCDS Jan 2013 Page 1 of 40 PACKAGE INSERT SCHEDULING STATUS Schedule 5 PROPRIETARY NAME AND DOSAGE FORM RISPERDAL 0,5 mg tablets. RISPERDAL 1 mg tablets. RISPERDAL 2 mg tablets. RISPERDAL 3 mg tablets. RISPERDAL 4 mg tablets. COMPOSITION

More information

CCDS Jan 2013 Page 1 of 40

CCDS Jan 2013 Page 1 of 40 PACKAGE INSERT SCHEDULING STATUS Schedule 5 PROPRIETARY NAME AND DOSAGE FORMS RISPERDAL QUICKLET 0,5 mg tablets RISPERDAL QUICKLET 1 mg tablets RISPERDAL QUICKLET 2 mg tablets RISPERDAL QUICKLET 3 mg tablets

More information

CCDS Jan 2013 Page 1 of 38

CCDS Jan 2013 Page 1 of 38 PACKAGE INSERT SCHEDULING STATUS Schedule 5 PROPRIETARY NAME AND DOSAGE FORM RISPERDAL 1 mg/ml oral solution COMPOSITION Each ml contains risperidone 1 mg. Preservatives: Benzoic acid 0,2 % m/v The solution

More information

MOTILIUM Tablets. What is in this leaflet. What MOTILIUM is used for. Before you take MOTILIUM. Domperidone base. Consumer Medicine Information

MOTILIUM Tablets. What is in this leaflet. What MOTILIUM is used for. Before you take MOTILIUM. Domperidone base. Consumer Medicine Information MOTILIUM Tablets Domperidone base Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about MOTILIUM tablets. It does not contain all the available information.

More information

PROPOSED PACKAGE INSERT. Each tablet contains 37,5 mg tramadol hydrochloride and 325 mg paracetamol as the active ingredients.

PROPOSED PACKAGE INSERT. Each tablet contains 37,5 mg tramadol hydrochloride and 325 mg paracetamol as the active ingredients. PROPOSED PACKAGE INSERT SCHEDULING STATUS Schedule 5 PROPRIETARY NAME AND DOSAGE FORM TRAMACET Tablets COMPOSITION Each tablet contains 37,5 mg tramadol hydrochloride and 325 mg paracetamol as the active

More information

DOMPERIDONE BNF 4.6. Domperidone is a dopamine type 2-receptor antagonist. It is structurally related to the

DOMPERIDONE BNF 4.6. Domperidone is a dopamine type 2-receptor antagonist. It is structurally related to the DOMPERIDONE BNF 4.6 Class: Prokinetic anti-emetic. Indications: Nausea and vomiting, dysmotility dyspepsia, gastro-oesophageal reflux. Pharmacology Domperidone is a dopamine type 2-receptor antagonist.

More information

Levocetirizine dihydrochloride

Levocetirizine dihydrochloride INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5

More information

*Gebaseer op die Nasionale Kanker Register Leeftyd risiko vir prostaatkanker 1:27. testikulêrekanker 1: peniskanker 1:1 114

*Gebaseer op die Nasionale Kanker Register Leeftyd risiko vir prostaatkanker 1:27. testikulêrekanker 1: peniskanker 1:1 114 *Gebaseer op die Nasionale Kanker Register 2010 Leeftyd risiko vir prostaatkanker 1:27 Leeftyd risiko vir testikulêrekanker Leeftyd risiko vir peniskanker 1:2 040 1:1 114 Prostaatkanker 1 uit 27 Suid-Afrikaanse

More information

AROMASIN 25mg (Tablets)

AROMASIN 25mg (Tablets) APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate

More information

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine

More information

VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology VI.2.2 Summary of treatment benefits

VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology VI.2.2 Summary of treatment benefits VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Nausea and vomiting are common ailments had by many individuals. Nausea is defined as the unpleasant, painless sensation that

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).

More information

KYNOBUFF IN CASE OF POISONING PLEASE PHONE / IN GEVAL VAN VERGIFTIGING SKAKEL l Netto Volume

KYNOBUFF IN CASE OF POISONING PLEASE PHONE / IN GEVAL VAN VERGIFTIGING SKAKEL l Netto Volume KYNOBUFF Reg. No.L4246, Act No./Wet Nr. 36 of/van 1947 A ph buffer for increasing the efficiency of ph sensitive agricultural remedies and improving the wetting and spreading properties of spray mixtures.

More information

CCDS May 2008 Page 1 of 26

CCDS May 2008 Page 1 of 26 PACKAGE INSERT SCHEDULING STATUS Schedule 6 PROPRIETARY NAME (and dosage form) SUFENTA FORTE injection COMPOSITION Each ml contains sufentanil citrate 0,075 mg equivalent to 0,050 mg of sufentanil base

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible

More information

Body weight more than 30kg : 10ml (10mg) of the syrup once daily.

Body weight more than 30kg : 10ml (10mg) of the syrup once daily. 1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose

More information

[Type text] Page 1 of 15

[Type text] Page 1 of 15 PACKAGE INSERT SCHEDULING STATUS Schedule 6 PROPRIETARY NAME (and dosage form) SUFENTA 2 ml injection SUFENTA 10 ml injection COMPOSITION Each ml contains sufentanil citrate 0,0075 mg equivalent to 0,005

More information

INSPRA 25 & 50 mg TABLETS

INSPRA 25 & 50 mg TABLETS INSPRA 25 & 50 mg TABLETS SCHEDULING STATUS: Schedule 4 PROPRIETARY NAMES (and dosage forms): INSPRA 25 (Tablets) INSPRA 50 (Tablets) COMPOSITION: INSPRA 25: INSPRA 50: Each tablet contains 25 mg eplerenone

More information

A water-soluble foliar feed with a wide range of nutrients for plants. n Wateroplosbare blaarvoeding met n wye reeks voedingselemente vir plante.

A water-soluble foliar feed with a wide range of nutrients for plants. n Wateroplosbare blaarvoeding met n wye reeks voedingselemente vir plante. FERTILIZER GROUP / MISSTOF GROEP II Reg. No. K 7652 Act/Wet 36 of/van 1947 1: 08/02/07 Oct 2013 Feed-P 2.1.2 (44) A water-soluble foliar feed with a wide range of nutrients for plants. n Wateroplosbare

More information

Cetirizine Proposed Core Safety Profile

Cetirizine Proposed Core Safety Profile Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function

More information

Hoe kan ek my maatjie wat kanker het help?

Hoe kan ek my maatjie wat kanker het help? Hoe kan ek my maatjie wat kanker het help? Wat is kanker? Kanker kan beskryf word as normale en gesonde selle in jou liggaam wat verander het in ongesonde kankerselle. Daar is baie redes vir hierdie veranderinge

More information

1. WHAT MOTILIUM IS AND WHAT IT IS USED FOR

1. WHAT MOTILIUM IS AND WHAT IT IS USED FOR MOTILIUM 10 mg FILM-COATED TABLETS Domperidone PATIENT INFORMATION LEAFLET This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help

More information

Page 1 of 30 SCHEDULING STATUS

Page 1 of 30 SCHEDULING STATUS SCHEDULING STATUS S6 PROPRIETARY NAMES AND DOSAGE FORM OxyContin 5 mg Prolonged Release Tablets OxyContin 10 mg Prolonged Release Tablets OxyContin 20 mg Prolonged Release Tablets OxyContin 40 mg Prolonged

More information

Page 1 of 31 SCHEDULING STATUS PROPRIETARY NAMES AND DOSAGE FORM. OxyContin 5 mg Prolonged Release Tablets. OxyContin 10 mg Prolonged Release Tablets

Page 1 of 31 SCHEDULING STATUS PROPRIETARY NAMES AND DOSAGE FORM. OxyContin 5 mg Prolonged Release Tablets. OxyContin 10 mg Prolonged Release Tablets SCHEDULING STATUS S6 PROPRIETARY NAMES AND DOSAGE FORM OxyContin 5 mg Prolonged Release Tablets OxyContin 10 mg Prolonged Release Tablets OxyContin 20 mg Prolonged Release Tablets OxyContin 40 mg Prolonged

More information

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:

Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: 0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR: 0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration

More information

APPROVED PACKAGE INSERT

APPROVED PACKAGE INSERT SCHEDULING STATUS S4 APPROVED PACKAGE INSERT PROPRIETARY NAME AND DOSAGE FORM SIMPONI Solution for Injection COMPOSITION Each 0,5 ml single use pre-filled syringe or pre-filled pen contains 50 mg of golimumab.

More information

PACKAGE INSERT. RISPERDAL CONSTA is an extended release microspheres formulation of risperidone, composed of

PACKAGE INSERT. RISPERDAL CONSTA is an extended release microspheres formulation of risperidone, composed of PACKAGE INSERT SCHEDULING STATUS Schedule 5. PROPRIETARY NAME AND DOSAGE FORM RISPERDAL CONSTA 25 mg prolonged release suspension for intramuscular injection. RISPERDAL CONSTA 37,5 mg prolonged release

More information

Rift Valley fever is a fever-causing viral disease that affects livestock and humans in Africa. It is most common during years of heavy rainfall.

Rift Valley fever is a fever-causing viral disease that affects livestock and humans in Africa. It is most common during years of heavy rainfall. Slenkdalkoors Slenkdalkoors is n erge insekgedraagde virussiekte wat hoefdiere soos skape, bokke en beeste aantas. Dit hou ook n ernstige gesondheidsgevaar vir die mens in. Diere word aanvanklik besmet

More information

VESIGARD Tablets (Darifenacin hydrobromide)

VESIGARD Tablets (Darifenacin hydrobromide) Published on: 10 Jul 2014 VESIGARD Tablets (Darifenacin hydrobromide) Composition VESIGARD 7.5 Extended Release Tablets Each tablet contains: Darifenacin (as a hydrobromide).. 7.5 mg Dosage Form Tablets

More information

Active ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg

Active ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg Name Primperan 10 mg / 2 ml Metoclopramide hydrochloride anhydrous Solution for I.M. or I.V. injection (Ampoules) Composition Each 2 ml ampoule contains: Active ingredients: Metoclopramide Hydrochloride.

More information

SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM. I.N.N. : Rilmenidine

SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM. I.N.N. : Rilmenidine SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM I.N.N. : Rilmenidine 1. DENOMINATION HYPERIUM 1 mg, tablets 2. COMPOSITION Rilmenidine (I.N.N.) dihydrogenphosphate.1.544 mg amount equivalent to rilmenidine

More information

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Telfast 120 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 120 mg of fexofenadine hydrochloride,

More information

PRUCAPLA Tablets (Prucalopride)

PRUCAPLA Tablets (Prucalopride) Published on: 2 May 2018 PRUCAPLA Tablets (Prucalopride) Composition PRUCAPLA 1 mg Each film coated tablet contains: Prucalopride succinate equivalent to Prucalopride 1 mg Excipients. q. s. Color: Titanium

More information

Composition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:

Composition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties: Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved

More information

PACKAGE INSERT. Each tablet contains the following active ingredients: 500 mg paracetamol,

PACKAGE INSERT. Each tablet contains the following active ingredients: 500 mg paracetamol, . PACKAGE INSERT SCHEDULING STATUS Schedule 2 PROPRIETARY NAME AND DOSAGE FORM SINUMAX WITH CODEINE tablets COMPOSITION Each tablet contains the following active ingredients: 500 mg paracetamol, 30 mg

More information

SIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.

SIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product. SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride

More information

PACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent

PACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) PARIET 10 mg tablets PARIET 20 mg tablets COMPOSITION 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole

More information

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications. Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically

More information

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fexofenadine hydrochloride 180 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 180mg

More information

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013

CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013 CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment

More information

MUSIEK - VOKAAL. 17 Augustus 20 Augustus Voorsitter: Lorraine Kirk

MUSIEK - VOKAAL. 17 Augustus 20 Augustus Voorsitter: Lorraine Kirk MUSIEK - VOKAAL 17 Augustus 20 Augustus 2015 Voorsitter: Lorraine Kirk - 082 689 2707 lorrainekirk58@gmail.com Die algemene reëls moet saam met die spesifieke reëls gelees word INSKRYWINGSFOOIE Solo R

More information

VERTE-X-PLODE Reg. No. B 3602 Act/Wet No. 36 of/van 1947

VERTE-X-PLODE Reg. No. B 3602 Act/Wet No. 36 of/van 1947 VERTE-X-PLODE Reg. No. B 3602 Act/Wet No. 36 of/van 1947 ACTIVE INGREDIENTS / AKTIEWE BESTANDDELE: K.51.3 g/kg P.40.7 g/kg Mo..41 mg/kg B.360 mg/kg Chelated / Cheleerd Fe.3942 mg/kg Mn.1440 mg/kg Zn..990

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR: Core Safety Profile Active substance: Flunarizine Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg P RMS: ES/H/PSUR/0013/001 Date of FAR: 13.12.2010 4.3 Contraindications Flunarizine is

More information

APPROVED PACKAGE INSERT

APPROVED PACKAGE INSERT Page 1 of 6 APPROVED PACKAGE INSERT SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: CYKLOKAPRON T 500 (Tablets) CYKLOKAPRON IV 500 (Injection) COMPOSITION: Each tablet contains 500 mg tranexamic

More information

Package Insert RDSR. 3. Pharmaceutical form Capsule containing enteric coated and sustained release pellets

Package Insert RDSR. 3. Pharmaceutical form Capsule containing enteric coated and sustained release pellets Package Insert RDSR Product Summary 1. Name of the medicinal product RDSR 2. Qualitative and quantitative composition Each capsule contains, Rabeprazole Sodium equivalent to Rabeprazole (as enteric coated

More information

ACTIVE INGREDIENT / AKTIEWE BESTANDDEEL: Brodifacoum (Anticoagulant) /Brodifakoum (Bloedstolweermiddel)..0,75 g / 500 m ; 1 Litre

ACTIVE INGREDIENT / AKTIEWE BESTANDDEEL: Brodifacoum (Anticoagulant) /Brodifakoum (Bloedstolweermiddel)..0,75 g / 500 m ; 1 Litre MAIN PANEL RODEX LIQUID BAIT Reg. No./Nr.: L9289 Act /Wet 36 /1947 A highly active anticoagulant liquid bait concentrate for the control of the Norway Rat (Rattus norwegicus), Roof Rat (Rattus rattus),

More information

Shaded areas=not MARKETED 24/2/09

Shaded areas=not MARKETED 24/2/09 PACKAGE INSERT SCHEDULING STATUS Schedule 6 PROPRIETARY NAME AND DOSAGE FORM RAPIFEN 2 ml IV injection RAPIFEN 10 ml IV injection COMPOSITION Each ml contains alfentanil hydrochloride 0,544 mg (equivalent

More information

Agreed Core Safety Profile for Budesonide nasal spray suspension and Budesonide nasal powder

Agreed Core Safety Profile for Budesonide nasal spray suspension and Budesonide nasal powder CSP Drug Budesonide Substance Date 13 Oct 2011 rev 11Nov Supersedes 18 Aug 2011 Agreed Core Safety Profile for DK/H/PSUR/0041/001 TABLE OF CONTENTS PAGE TITLE PAGE... 1 TABLE OF CONTENTS... 2 Introduction...

More information

acrylate vinylacetate-copolymer (adhesive), guar gum (absorbent), polyethylene terephathalate foil

acrylate vinylacetate-copolymer (adhesive), guar gum (absorbent), polyethylene terephathalate foil SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) EVOREL 25 Transdermal Delivery System (TDS) EVOREL 5 Transdermal Delivery System (TDS) EVOREL 75 Transdermal Delivery System (TDS) EVOREL

More information

0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR:

0BCore Safety Profile. Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) NL/H/PSUR/0058/001 Date of FAR: 0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Gastro-resistant capsules (10, 20, 40 mg) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 10.04.2013 CSP Drug Substance Omeprazole

More information

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION Farmadol Paracetamol 10 mg/ml INFUSION SOLUTION Composition Each ml contains: Paracetamol 10 mg Pharmacology Pharmacodynamic properties The precise mechanism of the analgesic and antipyretic properties

More information

Excipient with known effect: One tablet contains mg lactose monohydrate.

Excipient with known effect: One tablet contains mg lactose monohydrate. 1. NAME OF THE MEDICINAL PRODUCT Bicacta 50 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains 50 mg bicalutamide. Excipient with known effect: One tablet contains

More information

Ondansetron blocks the actions of chemicals in the body that can trigger nausea and vomiting.

Ondansetron blocks the actions of chemicals in the body that can trigger nausea and vomiting. 1 of 6 6/10/2016 4:54 PM Generic Name: ondansetron (oral) (on DAN se tron) Brand Names: Zofran, Zofran ODT, Zuplenz What is ondansetron? Ondansetron blocks the actions of chemicals in the body that can

More information

PRODUCT INFORMATION RESONIUM A. Na m

PRODUCT INFORMATION RESONIUM A. Na m PRODUCT INFORMATION RESONIUM A NAME OF THE MEDICINE Non-proprietary Name Sodium polystyrene sulfonate Chemical Structure CH - 2 CH SO 3 Na + n CAS Number 28210-41-5 [9003-59-2] CH 2 CH SO - 3 m DESCRIPTION

More information

M0BCore Safety Profile

M0BCore Safety Profile M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze

More information

Hoe om n DS160 in te vul, en so aansoeke te doen vir jou visum:

Hoe om n DS160 in te vul, en so aansoeke te doen vir jou visum: Hoe om n DS160 in te vul, en so aansoeke te doen vir jou visum: 1. Gaan na https://ceac.state.gov/genniv/ 2. Kies die konsulaat waarheen jy wil gaan en klik die Start an Application skakel. 3. Die webtuiste

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklonova 500 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tranexamic acid 500 mg. For the full list of excipients,

More information

SUMMARY OF PRODUCT CHARACTERISTICS. A 2.5ml single-dose bottle containing IU Cholecalciferol (equivalent to 625 micrograms vitamin D 3 )

SUMMARY OF PRODUCT CHARACTERISTICS. A 2.5ml single-dose bottle containing IU Cholecalciferol (equivalent to 625 micrograms vitamin D 3 ) SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fultium 25 000 IU Oral Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION A 2.5ml single-dose bottle containing 25 000 IU Cholecalciferol

More information

Each 1 ml of solution contains 50 micrograms palonosetron (as hydrochloride).

Each 1 ml of solution contains 50 micrograms palonosetron (as hydrochloride). Approved PI: 13 Jun 2014 Page 1 of 12 SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM ONICIT (solution for injection) COMPOSITION Each 1 ml of solution contains 50 micrograms palonosetron (as hydrochloride).

More information

NEOPYBUTHRIN. REG. NO. L4582 Act No. 36 of 1947 REG. NR. L4582 Wet Nr. 36 van 1947 Namibian Reg. No. N-AR 0592 Nambiese Reg. Nr.

NEOPYBUTHRIN. REG. NO. L4582 Act No. 36 of 1947 REG. NR. L4582 Wet Nr. 36 van 1947 Namibian Reg. No. N-AR 0592 Nambiese Reg. Nr. NEOPYBUTHRIN REG. NO. L4582 Act No. 36 of 1947 REG. NR. L4582 Wet Nr. 36 van 1947 Namibian Reg. No. N-AR 0592 Nambiese Reg. Nr. N-AR 0592 MISTING AND FOGGING SOLUTION FOR THE CONTROL OF COCKROACHES, HOUSE

More information

Data Sheet. BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other.

Data Sheet. BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other. BICALOX Data Sheet Bicalutamide 50 mg tablets Presentation BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other. Uses Actions

More information

SIFROL Composition Properties Indication

SIFROL Composition Properties Indication SIFROL Boehringer Composition 1 tablet contains: 0.125, 0.25 or 1.0 mg, (S)-2- amino-4,5,6,7-tetrahydro-6-propylamino-benzothiazole dihydrochloride monohydrate equivalent to 0.088, 0.18 or 0.7 mg pramipexole

More information

New Zealand Datasheet

New Zealand Datasheet New Zealand Datasheet Name of Medicine ONREX Tablets Ondansetron hydrochloride dihydrate tablets 4mg and 8mg. Presentation ONREX tablets 4 mg: White, circular, biconvex, film coated tablet debossed with

More information

MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350)

MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350) MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350) NAME OF THE MEDICINE: MOVICOL Liquid Orange Flavour, Concentrate for Oral Solution. DESCRIPTION: A clear colourless solution.

More information

A PLAY TECHNIQUE PROGRAMME FOR AUTISTIC CHILDREN IN MIDDLE CHILDHOOD

A PLAY TECHNIQUE PROGRAMME FOR AUTISTIC CHILDREN IN MIDDLE CHILDHOOD A PLAY TECHNIQUE PROGRAMME FOR AUTISTIC CHILDREN IN MIDDLE CHILDHOOD By CATHERINE ELIZABETH DAVIES SUBMITTED IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE DOCTOR PHILOSOPHIAE IN THE FACULTY

More information

CIZOREST Tablets (Amisulpride)

CIZOREST Tablets (Amisulpride) Published on: 2 Dec 2015 CIZOREST Tablets (Amisulpride) Composition CIZOREST 50mg Tablets Each film-coated tablet contains: Amisulpride..50 mg CIZOREST 100mg Tablets Each film-coated tablet contains: Amisulpride..100

More information

Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.

Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic

More information

DEPRESSIE101. panic attacks - inside the brain TALKING about anxiety attacks. hanteer angstigheid beter snellers vir 'n paniekaanval

DEPRESSIE101. panic attacks - inside the brain TALKING about anxiety attacks. hanteer angstigheid beter snellers vir 'n paniekaanval 9 A P R I L 2 0 1 8 U I T G A W E 2 5 DEPRESSIE101 panic attacks - inside the brain TALKING about anxiety attacks hanteer angstigheid beter snellers vir 'n paniekaanval PANIC ATTACKS: INSIDE THE BRAIN

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Flavamed Hustensaft 15 mg/5 ml oral solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of oral solution contains 3 mg ambroxol

More information

PRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.

PRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes. PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine

More information

M0BCore Safety Profile. Pharmaceutical form(s)/strength: several forms and strength DE/H/PSUR/0039/001 Date of FAR:

M0BCore Safety Profile. Pharmaceutical form(s)/strength: several forms and strength DE/H/PSUR/0039/001 Date of FAR: M0BCore Safety Profile Active substance: Pantoprazole Pharmaceutical form(s)/strength: several forms and strength P-RMS: DE/H/PSUR/0039/001 Date of FAR: 05.12.2013 Annex I : CSP 4.3 Contraindications Hypersensitivity

More information

Although this remedy has been extensively tested under a large variety of conditions the registration holder does not

Although this remedy has been extensively tested under a large variety of conditions the registration holder does not WARNINGS: THE FOLLOWING NUMBER OF DAYS MUST BE ALLOWED BETWEEN LAST APPLICATION AND HARVEST: Potatoes... 14 days Apples and Pears... 30 days Cruciferae... 3 days Peaches... 28 days Plums... 28 days Tobacco...

More information

EFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation

EFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation EFFECTIVE SHARED CARE AGREEMENT Dronedarone - For the treatment and management of atrial fibrillation Specialist details Patient identifier Name INTRODUCTION This shared care agreement outlines how the

More information

PRODUCT INFORMATION ANAGRAINE. Each ANAGRAINE tablet contains 5 mg metoclopramide and 500 mg paracetamol.

PRODUCT INFORMATION ANAGRAINE. Each ANAGRAINE tablet contains 5 mg metoclopramide and 500 mg paracetamol. PRODUCT INFORMATION ANAGRAINE COMPOSITION Each ANAGRAINE tablet contains 5 mg metoclopramide and 500 mg paracetamol. ACTIONS Metoclopramide stimulates gastrointestinal tract motility and accelerates gastric

More information

ALFUSIN Tablets (Alfuzosin hydrochloride)

ALFUSIN Tablets (Alfuzosin hydrochloride) Published on: 20 Sep 2014 ALFUSIN Tablets (Alfuzosin hydrochloride) Composition Each film-coated extended-release tablet contains: Alfuzosin hydrochloride Ph.Eur... 10 mg Dosage Form Extended-release tablet

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm Junior, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of contains the following active

More information

PRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets

PRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets

More information